News Ultragenyx, Mereo's brittle bone drug flames out in trials Two phase 3 trials of Ultragenyx and Mereo's sclerostin inhibitor setrusumab in osteogenesis imperfecta missed their primary efficacy objectives.
News Rumour mill says AstraZeneca may be eyeing a takeover of Mer... AstraZeneca is rumoured to be considering a bid to take control of its longstanding partner Mereo BioPharma, according to a
News UK biotech Mereo gears up for key brittle bone drug data UK biotech Mereo BioPharma is hoping the coming months will transform its fortunes as it prepares for potentially pivotal data for a brittle bone disease drug.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.